Rapid induction of allergen-blocking IgG in dogs vaccinated with plant-based, Der f 2-expressing bioparticles.
Der f 2
allergy
dog
house dust mites
immunotherapy
virus‐like particles
Journal
Veterinary dermatology
ISSN: 1365-3164
Titre abrégé: Vet Dermatol
Pays: England
ID NLM: 9426187
Informations de publication
Date de publication:
02 Sep 2024
02 Sep 2024
Historique:
revised:
12
05
2024
received:
30
10
2023
accepted:
06
08
2024
medline:
3
9
2024
pubmed:
3
9
2024
entrez:
2
9
2024
Statut:
aheadofprint
Résumé
Allergen-carrying virus-like particles are effective and safe means of allergen immunotherapy (AIT) in rodent models. To study the development of allergen-blocking immunoglobulin (Ig)G in dogs injected with Der f 2-carrying enveloped plant-based bioparticles (eBPs). Laboratory beagle dogs were injected intradermally (ID) or subcutaneously (SC) with Der f 2-eBP three times at 2-week intervals. A basophil mediator release assay was used to compare the reactivity of Der f 2-eBPs to that of recombinant Der f 2. Allergen-specific IgG serum levels were determined by immunoblotting and ELISA. The allergen-blocking potential of postvaccination IgG was assessed by Pet Allergy Xplorer (PAX) macroarray and basophil mediator release inhibition assays. The amount of Der f 2 eBPs needed to induce basophil activation was 1000-fold higher than that of the soluble natural allergen. In both immunisation groups, eBP injections caused no adverse events and induced Der f 2-specific IgG, first detected on Day (D)14 and peaking on D41. The co-incubation of sera with a Der f 2-IgE-rich canine serum pool resulted in a mean PAX inhibition of 70% (ID) to 80% (SC) on D41. For both groups, the inhibition of basophil mediator release reached 75% on D28 and D41. The percentage inhibition of PAX and mediator release correlated significantly with Der f 2 IgG levels. Intradermal and subcutaneous injections of Der f 2-eBPs were safe and increased Der f 2-specific IgG. The clinical benefit of immunotherapy will be evaluated in future trials enrolling atopic dogs allergic to house dust mites.
Sections du résumé
BACKGROUND
BACKGROUND
Allergen-carrying virus-like particles are effective and safe means of allergen immunotherapy (AIT) in rodent models.
OBJECTIVE
OBJECTIVE
To study the development of allergen-blocking immunoglobulin (Ig)G in dogs injected with Der f 2-carrying enveloped plant-based bioparticles (eBPs).
MATERIALS AND METHODS
METHODS
Laboratory beagle dogs were injected intradermally (ID) or subcutaneously (SC) with Der f 2-eBP three times at 2-week intervals. A basophil mediator release assay was used to compare the reactivity of Der f 2-eBPs to that of recombinant Der f 2. Allergen-specific IgG serum levels were determined by immunoblotting and ELISA. The allergen-blocking potential of postvaccination IgG was assessed by Pet Allergy Xplorer (PAX) macroarray and basophil mediator release inhibition assays.
RESULTS
RESULTS
The amount of Der f 2 eBPs needed to induce basophil activation was 1000-fold higher than that of the soluble natural allergen. In both immunisation groups, eBP injections caused no adverse events and induced Der f 2-specific IgG, first detected on Day (D)14 and peaking on D41. The co-incubation of sera with a Der f 2-IgE-rich canine serum pool resulted in a mean PAX inhibition of 70% (ID) to 80% (SC) on D41. For both groups, the inhibition of basophil mediator release reached 75% on D28 and D41. The percentage inhibition of PAX and mediator release correlated significantly with Der f 2 IgG levels.
CONCLUSION AND CLINICAL RELEVANCE
CONCLUSIONS
Intradermal and subcutaneous injections of Der f 2-eBPs were safe and increased Der f 2-specific IgG. The clinical benefit of immunotherapy will be evaluated in future trials enrolling atopic dogs allergic to house dust mites.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 ESVD and ACVD.
Références
Dorofeeva Y, Shilovskiy I, Tulaeva I, Focke‐Tejkl M, Flicker S, Kudlay D, et al. Past, present, and future of allergen immunotherapy vaccines. Allergy. 2021;76:131–149.
Pali‐Schöll I, DeBoer DJ, Alessandri C, Seida AA, Mueller RS, Jensen‐Jarolim E. Formulations for allergen immunotherapy in human and veterinary patients: new candidates on the horizon. Front Immunol. 2020;11:1697.
Durham SR, Shamji MH. Allergen immunotherapy: past, present and future. Nat Rev Immunol. 2023;23:317–328.
Gomord V, Stordeur V, Fitchette A‐C, Fixman ED, Tropper G, Garnier L, et al. Design, production and immunomodulatory potency of a novel allergen bioparticle. PLoS One. 2020;15:e0242867.
Busold S, Aglas L, Menage C, Auger L, Desgagnés R, Faye L, et al. Fel d 1 surface expression on plant‐made eBioparticles combines potent immune activation and hypoallergenicity. Allergy. 2022;77:3124–3126.
Castenmiller C, Stigler M, Kirpas ME, Versteeg S, Akkerdaas JH, Pena‐Castellanos G, et al. Plant‐based enveloped Ara h 2 bioparticles display exceptional hypo‐allergenicity. Clin Exp Allergy. 2023;53:577–581.
Favrot C, Olivry T, Iwasaki T. An international seroprevalence survey of the IgE sensitisation to the Dermatophagoides farinae house dust mite and two of its major allergens (Der f 2, Zen 1) in atopic dogs. Vet Dermatol. 2022;33:117‐e34.
Wenger M, Bethanis A, Johnson L, Aglas L. Humanized mediator release assay as a read‐out for allergen potency. J Vis Exp. 2021;172:e62702. https://doi.org/10.3791/62702
Hammerberg B, Bevier D, DeBoer DJ, Olivry T, Orton SM, Gebhard D, et al. Auto IgG anti‐IgE and IgG x IgE immune complex presence and effects on ELISA‐based quantitation of IgE in canine atopic dermatitis, demodectic acariasis and helminthiasis. Vet Immunol Immunopathol. 1997;60:33–46.
Chruszcz M, Kapingidza AB, Dolamore C, Kowal K. A robust method for the estimation and visualization of IgE cross‐reactivity likelihood between allergens belonging to the same protein family. PLoS One. 2018;13:e0208276.
de Blay FJ, Gherasim A, Domis N, Meier P, Shawki F, Wang CQ, et al. REGN1908/1909 prevented cat allergen‐induced early asthmatic responses in an environmental exposure unit. J Allergy Clin Immunol. 2022;150:1437–1446.
Castenmiller C, Nagy NA, Kroon PZ, Auger L, Desgagnés R, Martel C, et al. A novel peanut allergy immunotherapy: plant‐based enveloped Ara h 2 bioparticles activate dendritic cells and polarize T cell responses to Th1. World Allergy Organ J. 2023;16:100839.
Zha L, Leoratti FMS, He L, Mohsen MO, Cragg M, Storni F, et al. An unexpected protective role of low‐affinity allergen‐specific IgG through the inhibitory receptor FcγRIIb. J Allergy Clin Immunol. 2018;142:1529–1536.e6.
Orengo JM, Radin AR, Kamat V, Badithe A, Ben LH, Bennett BL, et al. Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement. Nat Commun. 2018;9:1421.
Shamji MH, Singh I, Layhadi JA, Ito C, Karamani A, Kouser L, et al. Passive prophylactic administration with a single dose of anti‐Fel d 1 monoclonal antibodies REGN1908‐1909 in cat allergen‐induced allergic rhinitis: a randomized, double‐blind, placebo‐controlled clinical trial. Am J Respir Crit Care Med. 2021;204:23–33.
Kamal MA, Dingman R, Wang CQ, Lai C‐H, Rajadhyaksha M, DeVeaux M, et al. REGN1908‐1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: translational pharmacokinetics and pharmacodynamics. Clin Transl Sci. 2021;14:2440–2449.
Gevaert P, De Craemer J, De Ruyck N, Rottey S, de Hoon J, Hellings PW, et al. Novel antibody cocktail targeting bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study. J Allergy Clin Immunol. 2022;149:189–199.
Paolucci M, Wuillemin N, Homère V, Bieli D, Köhli A, Ballmer‐Weber B, et al. Targeting Ara h 2 with human‐derived monoclonal antibodies prevents peanut‐induced anaphylaxis in mice. Allergy. 2023;78:1605–1614.